Endo, Inc. (NDOI)
| Market Cap | 1.80B |
| Revenue (ttm) | 1.73B -9.5% |
| Net Income | 5.67B |
| EPS | 65.93 |
| Shares Out | 76.31M |
| PE Ratio | 0.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 537 |
| Open | 23.54 |
| Previous Close | 23.10 |
| Day's Range | 23.50 - 23.59 |
| 52-Week Range | 19.85 - 31.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2025 |
About Endo, Inc.
Endo, Inc. operates as a specialty pharmaceutical company that develops, manufactures, markets, and sells various pharmaceutical products and provides life-enhancing therapies in the United States and internationally. It offers specialty medicines, sterile injectables, and generic products. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It also develops additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others in pr... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Chiesi Global Rare Diseases Highlights Advancements in Lipodystrophy Research at ENDO 2026
-- Presentations highlight new clinical, real-world, and patient-centered insights on metreleptin across lipodystrophy populations -- -- Presentations highlight new clinical, real-world, and patient-c...
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect –
Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generati...
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD) Urinary free co...
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New resul...
OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
MENLO PARK, Calif.--(BUSINESS WIRE)-- #ClinicalData--OrsoBio presents positive Phase 2a data for its LXR inverse agonist TLC-2716 in SHTG and MASLD at ENDO 2026.
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Upcoming presentations at ENDO 2026 highlight Lundbeck's Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needs The scientific program showc...
PRM and Project Endo Launch National University Health Initiative to Improve Early Endometriosis Recognition on College Campuses
The founding partnership equips university health centers with free screening tools, educational resources, and referral pathways to help students access specialized pelvic pain and endometriosis care...
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generati...
Endometrics Wins First Prize in NIH RADx Tech ACT ENDO Challenge
SAN FRANCISCO--(BUSINESS WIRE)-- #Diagnostics--Endometrics announced it has won first prize in the NIH RADx Tech ACT ENDO Challenge.
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun Off as an Independent ...
Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting
MALVERN, Pa. , July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during t...
Endo to Report Second Quarter 2025 Financial Results on August 6, 2025
MALVERN, Pa. , July 21, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it will report second quarter 2025 financial results on August 6, 2025, prior to ma...
Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc.
Closing of the Merger Expected in Early August DUBLIN , July 17, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that the Irish High Court has given the necessary ruling to enable its combinati...
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #biotech--Aspect Biosystems presents preclinical data showing potential of its adrenal BTTs to restore adrenal function and treat primary adrenal insuffi...
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generati...
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
PRESS RELEASE OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH e...
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generati...
Endo Completes International Pharmaceuticals Business Divestiture
MALVERN, Pa. , June 17, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmace...
Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader
Mallinckrodt to Apply to Irish High Court for Approval of Scheme of Arrangement DUBLIN and MALVERN, Pa. , June 13, 2025 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) (...
Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
Experienced and Highly Capable Senior Executives to Lead both the Branded Specialty Pharmaceutical and Generics & Sterile Injectables Businesses Generics & Sterile Injectables Spin-Off to be Called Pa...
Endo Champions Men's Health Month with Education, Awareness, and Outreach
MALVERN, Pa. , June 2, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health and addressing health issue...
ENDO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Endo, Inc. - NDOI
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger o...
Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration
Endo's products are the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag MALVERN, Pa. , May 15, 2025 /PRNewswire/ -- End...
Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
S-4 Registration Statement Effective; HSR Waiting Period Expired Irish High Court Approves Convening of Shareholder Meetings Shareholder Vote Scheduled for June 13 DUBLIN and MALVERN, Pa. , May 13, 20...